/Henry%20Schein%20Inc_%20sign%20outside%20office-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Henry Schein, Inc. (HSIC), headquartered in Melville, New York, provides healthcare products and services to dental practitioners, laboratories, physician practices, ambulatory surgery centers, government, institutional healthcare clinics, and other alternate care clinics. Valued at $8.96 billion by market cap, the company operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products. Its network of advisors provides over one million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. The leading distributor of medical and dental supplies is expected to announce its fiscal second-quarter earnings for 2024 before the market opens on Tuesday, Aug. 6.
Ahead of the event, analysts expect HSIC to report a profit of $1.27 per share on a diluted basis, down 3.1% from $1.31 per share in the year-ago quarter. The company beat or matched the consensus estimates in three of the last four quarters while missing on one other occasion.
For fiscal 2024, analysts expect HSIC to report EPS of $5.16, up 14.7% from $4.50 in fiscal 2023.
HSIC stock has underperformed the S&P 500’s ($SPX) 16.5% gains on a YTD basis, with shares down 7.6% during this period. Similarly, it underperformed the S&P 500 Healthcare Sector SPDR’s (XLV) 9% gains over the same time frame.
On May 7, HSIC reported its Q1 results. Its adjusted EPS was $1.10, beating the consensus estimates of $0.99. The company’s revenue of $3.17 billion fell short of Wall Street expectations of $3.23 billion. For the full-year 2024, HSIC expects non-GAAP EPS to be between $5 and $5.16 and adjusted EBITDA growth of more than 15%. Moreover, it tightened the total sales growth guidance range to 8% to 10%. HSIC shares closed up more than 3% on the day the results were released.
Analysts’ consensus opinion on HSIC stock is bullish, with a “Moderate Buy” rating overall. Out of 13 analysts covering the stock, five advise a “Strong Buy” rating, six have a “Hold” rating, one recommends a “Moderate Sell” rating, and one gives a “Strong Sell.” The average analyst price target for HSIC is $78, indicating an 11.4% potential upside from the current levels.
On the date of publication, Dipanjan Banchur did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
